Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROPAMIDE versus DIABINESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROPAMIDE versus DIABINESE.
CHLORPROPAMIDE vs DIABINESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
Initial: 250 mg orally once daily, increase by 125-250 mg every 1-2 weeks as needed. Maintenance: 100-500 mg once daily. Maximum: 750 mg daily.
None Documented
None Documented
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Terminal elimination half-life 25–36 hours; in renal impairment, half-life prolonged significantly.
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Primarily renal (up to 80% unchanged); minor fecal (biliary) excretion (<10%).
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."